Additional file 1 of A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

  • Chien-Liang Wu (Creator)
  • Cheng Kuo Cheng (Contributor)
  • Pei Chang Wu (Creator)
  • Arslan Tsai (Creator)
  • Jiann Torng Chen (Contributor)
  • Yun-Dun Shen (Contributor)
  • Wen Chuan Wu (Creator)
  • Ching Yao Tsai (Creator)



Additional file 1: Table S1. Eligibility Criteria for NHI reimbursement [4]. Table S2. Colour fundus photography results compared with baseline (ITT population). Table S3.Baseline demographics, ocular and disease characteristics for patients with nAMD treated with ranibizumab 0.5 mg, by subgroups (ITT population).
Date made available2020

Cite this